Purpose: Response rates to immune checkpoint blockade (ICB; anti-PD-1/anti-CTLA-4)
correlate with the extent of tumor immune infiltrate, but the mechanisms underlying the …

Adenosine is an immunosuppressive factor that limits anti-tumor immunity through the
suppression of multiple immune subsets including T cells via activation of the adenosine A 2A …

Adoptive cell therapies using genetically engineered T cell receptor or chimeric antigen
receptor T cells are emerging forms of immunotherapy that redirect T cells to specifically target …

Memory CD8 + T cells can be broadly divided into circulating (T CIRCM ) and tissue-resident
memory T (T RM ) populations. Despite well-defined migratory and transcriptional …

Chimeric antigen receptor (CAR) T cell therapy has been highly successful in hematological
malignancies leading to their US Food and Drug Administration (FDA) approval. However, …

The function of MR1-restricted mucosal-associated invariant T (MAIT) cells in tumor
immunity is unclear. Here we show that MAIT cell-deficient mice have enhanced NK cell-dependent …

Immunotherapy is widely accepted as a powerful new treatment modality for the treatment of
cancer. The most successful form of immunotherapy to date has been the blockade of the …

CXCL9 expression is a strong predictor of response to immune checkpoint blockade therapy.
Accordingly, we sought to develop therapeutic strategies to enhance the expression of …

CRISPR/Cas9 technologies have revolutionized our understanding of gene function in complex
biological settings, including T cell immunology. Current CRISPR-mediated gene editing …

The production and delivery of functional perforin (PRF; PRF1 gene) by cytotoxic lymphocytes
maintains immune homeostasis and tumour immune surveillance. In humans, inheritance …